All In Biotech

Drug Trial Radar · NCT04194957

Improving the Safety of Fluoropyrimidine-based Chemotherapy

Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study

Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,440

Planned (sponsor's estimate)

Start

Jan 15, 2020

Primary completion

Jan 2021

Study completion Jan 2021

Sponsor

Lead sponsor
The Netherlands Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Leiden University Medical Center
First posted
Dec 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study it will be determined whether the rate of severe toxicity associated with fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished by individualized dosing of fluoropyrimidines based on upfront phenotypic assessment of dihydropyrimidine dehydrogenase (DPD) deficiency.

Conditions

  • Neoplasms

Interventions

  • Fluoropyrimidine (capecitabine or 5-fluorouracil)Drug

    Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.

  • Fluoropyrimidine (capecitabine or 5-fluorouracil)Drug

    Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.

  • Fluoropyrimidine (capecitabine or 5-fluorouracil)Drug

    Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: incidence of severe fluoropyrimidine-related toxicity (CTCAE grade 3 to 5) in wild type patientsTime frame: Patients with a pre-treatment uracil concentration above 16 ng/ml will be followed until end of treatment (expected average of 1 year). Otherwise, patients will be followed for the first 2 cycles (each cycle is 28 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Netherlands Cancer Institute - Antoni van Leeuwenhoek

    Amsterdam, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.